Bimatoprost/timolol

Drug Profile

Bimatoprost/timolol

Alternative Names: Ganfort; Lumigan/timolol; Timolol/bimatoprost; Unit Dose Ganfort

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Amides; Antiglaucomas; Antihypertensives; Lipids; Morpholines; Propanolamines; Synthetic prostaglandins; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Glaucoma in China (Ophthalmic, Drops)
  • 01 Jan 2013 Allergan files for approval of a preservative-free bimatoprost/timolol formulation in the EU
  • 17 Nov 2011 Launched for Glaucoma in Mexico (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top